AMRA and Pfizer have collaborated with the aim of potentially identifying patients most at risk from metabolic disease and comorbidities.

The companies will evaluate the relationship between fat and muscle distribution in the body and metabolic health, including risk factors for conditions such as obesity and diabetes.

Read full story